Registration Number
0213U000541,
0111U000377
, R & D reports
Title
Developing of the maintenance therapy in breast cancer patients who receive chemotherapy, considering clinical and laboratory of toxicity prognosis factors
popup.stage_title
Head
Syvak Liubov,
Registration Date
14-02-2013
Organization
Ukrainian Research Institute of Oncology and Radiology
popup.description2
The object of study - 130 patients with malignant breast tumors with toxic effects of chemotherapy regimen FAC. Purpose - to improve the results of chemotherapy and quality of life in patients with malignant breast tumors by developing maintenance therapy based on the clinical and laboratory prediction factors of toxicity of anticancer drugs. Methods and apparatus: clinical, laboratory, instrumental, statistical, ultrasound machine "Aloca", hematology analyzer BC-3000 biochemical analyzer "Vitros", spectrophotometer "Thermo", a high-speed centrifuge "Biofuge", Thermostat "Termyt." As a result of clinical (complaints, physical data), laboratory (hemogram with differential count and erythrocyte sedimentation rate, blood chemistries, urinalysis), instrumental (ECG, echocardiography, chest cavity, abdominal ultrasound or computed tomography chest, abdomen and pelvis with contrast enhancement) research and analysis of molecular genetic parameters (gene polymorphism GSTP1, MTHFR, protein expression ITSN2) during chemotherapy regimen FAC (4-6 cycles) in patients with malignant breast tumors found that the regimen has a moderate (II-III) toxicity rate, the main manifestations of which are gastrointestinal (95.4%), cardiovascular (16.1%) and hematological (1.6%) toxicity. The most important prognostic factors for chemotherapy toxicity regimen FAC in patients with malignant breast tumors include age over 45 years, concomitant diseases, especially cardiovascular system and gastrointestinal tract, cancerstage, previous anticancer treatment and the presence of the mutant allele G gene GSTP1 and T allele of the gene MTHFR. Algorithm of the support therapy implementation in patients with malignant breast tumors with a high risk of complications allowed to perform chemotherapy timely, reduce the appearance of gastrointestinal toxicity in 80.5% and early cardiotoxicity - in 56.2% patient. Quality of life and outcomeswere also improved. Field of implementation: oncology.
Product Description
popup.authors
Алексик Олена Олексіївна
Аскольський Антон Вячеславович
Губарева Ганна Олександрівна
Кліманов Михайло Юрійович
Лялькін Сергій Анатолійович
Майданевич Наталя Миколаївна
Свергун Наталя Миколаївна
Сивак Любов Андріївна
Філоненко Катерина Сергіївна
Шевчук Леся Анатоліївна
popup.nrat_date
2020-04-02
